Risk of rash associated with lenalidomide in cancer patients: A systematic review of the literature and meta-analysis

Beatrice Nardone; Shenhong Wu; Benjamin C. Garden; Dennis P. West; Lilian M. Reich; Mario E. Lacouture

doi:10.1016/j.clml.2013.03.006

Risk of rash associated with lenalidomide in cancer patients: A systematic review of the literature and meta-analysis

Beatrice Nardone, Shenhong Wu, Benjamin C. Garden, Dennis P. West, Lilian M. Reich, Mario E. Lacouture^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Background: Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes. The incidence and risk of rash has been inconsistently reported. Materials and Methods: We conducted a systematic review and metaanalysis of the literature to determine the incidence and risk of developing rash. Relevant studies were identified from PubMed and abstracts presented at American Society of Clinical Oncology annual meetings. Incidence, relative risk, and 95% confidence intervals were calculated. Results: Ten trials were available for analysis, and the overall incidence of all-grade and high-grade rash was 27.2% and 3.6%, respectively. Lenalidomide was associated with increased risk of all-grade rash (P <.001). Conclusion: Further studies for prevention and treatment of this toxicity are needed to minimize effect on quality of life and dose intensity.

Original language	English (US)
Pages (from-to)	424-429
Number of pages	6
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	13
Issue number	4
DOIs	https://doi.org/10.1016/j.clml.2013.03.006
State	Published - Aug 2013

Keywords

Lenalidomide
Multiple myeloma
Myelodyplastic syndrome
Rash
Skin toxicities

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2013.03.006

Cite this

@article{fa594b5c85024b44baed69ec00011883,

title = "Risk of rash associated with lenalidomide in cancer patients: A systematic review of the literature and meta-analysis",

abstract = "Background: Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes. The incidence and risk of rash has been inconsistently reported. Materials and Methods: We conducted a systematic review and metaanalysis of the literature to determine the incidence and risk of developing rash. Relevant studies were identified from PubMed and abstracts presented at American Society of Clinical Oncology annual meetings. Incidence, relative risk, and 95% confidence intervals were calculated. Results: Ten trials were available for analysis, and the overall incidence of all-grade and high-grade rash was 27.2% and 3.6%, respectively. Lenalidomide was associated with increased risk of all-grade rash (P <.001). Conclusion: Further studies for prevention and treatment of this toxicity are needed to minimize effect on quality of life and dose intensity.",

keywords = "Lenalidomide, Multiple myeloma, Myelodyplastic syndrome, Rash, Skin toxicities",

author = "Beatrice Nardone and Shenhong Wu and Garden, {Benjamin C.} and West, {Dennis P.} and Reich, {Lilian M.} and Lacouture, {Mario E.}",

note = "Funding Information: Funding source: Career Development Award from the Dermatology Foundation (MEL). ",

year = "2013",

month = aug,

doi = "10.1016/j.clml.2013.03.006",

language = "English (US)",

volume = "13",

pages = "424--429",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "4",

}

TY - JOUR

T1 - Risk of rash associated with lenalidomide in cancer patients

T2 - A systematic review of the literature and meta-analysis

AU - Nardone, Beatrice

AU - Wu, Shenhong

AU - Garden, Benjamin C.

AU - West, Dennis P.

AU - Reich, Lilian M.

AU - Lacouture, Mario E.

N1 - Funding Information: Funding source: Career Development Award from the Dermatology Foundation (MEL).

PY - 2013/8

Y1 - 2013/8

N2 - Background: Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes. The incidence and risk of rash has been inconsistently reported. Materials and Methods: We conducted a systematic review and metaanalysis of the literature to determine the incidence and risk of developing rash. Relevant studies were identified from PubMed and abstracts presented at American Society of Clinical Oncology annual meetings. Incidence, relative risk, and 95% confidence intervals were calculated. Results: Ten trials were available for analysis, and the overall incidence of all-grade and high-grade rash was 27.2% and 3.6%, respectively. Lenalidomide was associated with increased risk of all-grade rash (P <.001). Conclusion: Further studies for prevention and treatment of this toxicity are needed to minimize effect on quality of life and dose intensity.

AB - Background: Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes. The incidence and risk of rash has been inconsistently reported. Materials and Methods: We conducted a systematic review and metaanalysis of the literature to determine the incidence and risk of developing rash. Relevant studies were identified from PubMed and abstracts presented at American Society of Clinical Oncology annual meetings. Incidence, relative risk, and 95% confidence intervals were calculated. Results: Ten trials were available for analysis, and the overall incidence of all-grade and high-grade rash was 27.2% and 3.6%, respectively. Lenalidomide was associated with increased risk of all-grade rash (P <.001). Conclusion: Further studies for prevention and treatment of this toxicity are needed to minimize effect on quality of life and dose intensity.

KW - Lenalidomide

KW - Multiple myeloma

KW - Myelodyplastic syndrome

KW - Rash

KW - Skin toxicities

UR - http://www.scopus.com/inward/record.url?scp=84880710047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880710047&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.03.006

DO - 10.1016/j.clml.2013.03.006

M3 - Article

C2 - 23769670

AN - SCOPUS:84880710047

SN - 2152-2650

VL - 13

SP - 424

EP - 429

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 4

ER -

Risk of rash associated with lenalidomide in cancer patients: A systematic review of the literature and meta-analysis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this